remain
genuin
need
explor
aetiolog
pathogenesi
aecopd
anticip
result
studi
increas
understand
contribut
bacteri
viral
pathogen
aecopd
potenti
lead
research
target
therapeut
prevent
intervent
conduct
specialis
hospit
extens
experi
respiratori
research
comprehens
assess
clinic
statu
microbiolog
function
statu
nutrit
statu
healthrel
qualityoflif
healthcar
resourc
utilis
individu
patient
singl
larg
cohort
stabl
copd
aecopd
aecopd
proactiv
identifi
patientcomplet
electron
diari
cohort
retent
key
factor
success
deliveri
studi
indepth
sampl
protocol
particip
engag
comfort
feedback
key
factor
optimis
cohort
retent
comprehens
data
collect
chronic
obstruct
pulmonari
diseas
copd
inflammatori
diseas
lung
characteris
progress
airflow
limit
fulli
revers
copd
common
chronic
respiratori
ill
older
adult
affect
estim
million
peopl
worldwid
condit
substanti
impact
qualityoflif
global
burden
diseas
studi
found
copd
third
lead
caus
death
global
ninth
lead
caus
year
life
lost
due
prematur
mortal
account
year
live
disabl
disabilityadjust
life
year
worldwid
copd
also
impos
substanti
socioeconom
burden
total
cost
copd
europ
report
billion
consider
progress
made
concern
epidemiolog
pathophysiolog
clinic
manag
copd
recent
year
howev
signific
challeng
remain
improv
understand
acut
exacerb
copd
aecopd
key
research
prioriti
aecopd
highli
relev
clinic
major
caus
copdrel
morbid
mortal
well
account
substanti
proport
signific
social
healthcar
econom
burden
copd
estim
aecopd
account
approxim
total
healthcar
cost
associ
copd
patient
global
initi
chronic
obstruct
lung
diseas
gold
stage
ii
diseas
experi
exacerb
annual
exacerb
vari
patient
patient
sever
diseas
variou
trigger
aecopd
identifi
howev
exacerb
associ
detect
bacteri
andor
viral
respiratori
pathogen
exacerb
associ
detect
respiratori
pathogen
shown
mark
impact
introduct
new
molecular
sequenc
techniqu
tradit
belief
healthi
lung
steril
refut
increas
evid
lower
respiratori
tract
contain
divers
microbi
flora
differ
health
diseas
presenc
potenti
pathogen
microorgan
inflam
airway
patient
copd
welldocu
patient
stabl
copd
show
evid
lower
airway
bacteri
colonis
use
tradit
cultur
techniqu
patient
copd
bacteri
detect
lower
airway
deriv
sampl
associ
increas
airway
inflamm
reduc
lung
function
frequent
exacerb
acquisit
new
pathogen
strain
also
appear
associ
increas
risk
aecopd
estim
rel
contribut
differ
pathogen
aecopd
vari
howev
nontyp
haemophilu
influenza
appear
major
bacteri
pathogen
associ
aecopd
follow
streptococcu
pneumonia
moraxella
catarrhali
pseudomona
aeruginosa
respiratori
virus
commonli
associ
aecopd
includ
human
rhinovirus
influenza
parainfluenza
virus
respiratori
syncyti
viru
coronaviru
adenoviru
improv
understand
role
infecti
pathogen
aecopd
may
lead
develop
target
strategi
treatment
prevent
primari
object
aeri
studi
estim
incid
allcaus
aecopd
aecopd
sputum
contain
bacteri
pathogen
overal
speci
secondari
studi
object
summaris
tabl
tabl
overview
primari
secondari
object
aeri
studi
level
object
primari
estim
incid
rate
allcaus
aecopd
estim
incid
rate
aecopd
sputum
contain
bacteri
pathogen
overal
speci
describ
proport
overal
specif
bacteri
pathogen
detect
sputum
sever
aecopd
describ
proport
overal
specif
bacteri
pathogen
detect
sputum
stabl
copd
estim
incid
rate
aecopd
sputum
contain
viral
pathogen
overal
speci
describ
proport
overal
specif
viral
pathogen
detect
sputum
sever
aecopd
estim
time
elaps
consecut
aecopd
episod
assess
impact
allcaus
aecopd
stabl
copd
healthrel
qualityoflif
assess
impact
healthcar
use
allcaus
aecopd
aecopd
sputum
contain
bacteri
pathogen
aecopd
sputum
contain
viral
pathogen
aecopd
acut
exacerb
chronic
obstruct
pulmonari
diseas
ongo
singlecentr
prospect
observ
cohort
studi
base
univers
hospit
southampton
uk
male
femal
copd
patient
age
tabl
studi
inclus
exclus
criteria
inclus
criteria
subject
must
satisfi
follow
criteria
studi
entri
subject
investig
believ
compli
requir
protocol
exclus
criteria
confirm
diagnosi
asthma
caus
obstruct
respiratori
disord
cystic
fibrosi
pneumonia
risk
factor
respiratori
disord
eg
tuberculosi
lung
cancer
histori
lung
surgeri
antitrypsin
defici
underli
caus
copd
moder
sever
copd
exacerb
resolv
least
month
prior
enrol
less
day
follow
last
dose
oral
corticosteroid
addit
daili
monitor
undertaken
patientcomplet
electron
diari
card
wide
rang
studi
procedur
perform
studi
entri
schedul
monthli
visit
exacerb
visit
tabl
cultur
isol
also
store
addit
laboratori
test
perform
gsk
design
laboratori
sampl
size
calcul
base
primari
studi
endpoint
incid
sampl
size
subject
ensur
suffici
precis
estim
incid
rate
allcaus
aecopd
addit
order
follow
effect
subject
given
fact
subject
may
elig
withdraw
quit
earli
studi
possibl
due
f
r
p
e
e
r
r
e
v
e
w
n
l
deterior
subject
health
decis
taken
replac
subject
withdrew
first
year
followup
recruit
addit
subject
coprimari
studi
endpoint
occurr
allcaus
aecopd
occurr
aecopd
sputum
contain
bacteri
pathogen
detect
cultur
overal
speci
proport
subject
visit
sputum
sampl
obtain
comput
overal
method
sampl
obtain
spontan
induc
proport
sputum
sampl
obtain
visit
posit
specif
bacteri
pathogen
overal
bacteri
speci
also
calcul
incid
rate
allcaus
aecopd
aecopd
sputum
contain
bacteri
pathogen
overal
bacteri
speci
calcul
ci
ci
incid
rate
comput
use
model
account
repeat
event
name
generalis
linear
model
assum
neg
binomi
distribut
respons
variabl
logarithm
link
function
logarithm
time
followup
offset
variabl
preliminari
approach
flexibl
approach
statist
analysi
may
also
use
addit
model
covari
eg
smoke
statu
enrol
number
moderatesever
exacerb
report
month
prior
enrol
presenc
respiratori
pathogen
bacteria
detect
exacerb
visit
previou
visit
appli
incid
rate
also
calcul
moder
aecopd
sever
aecopd
aeri
studi
conduct
accord
declar
helsinki
good
clinic
practic
guidelin
approv
relev
institut
result
obtain
dissemin
present
intern
medic
confer
peerreview
public
aeri
studi
initi
assess
role
infecti
pathogen
aecopd
wellcharacteris
cohort
patient
studi
aim
explor
dynam
airway
infect
possibl
contribut
aecopd
well
potenti
role
chronic
colon
stabl
diseas
overal
object
studi
aim
refin
case
definit
aecopd
reflect
possibl
microbiolog
aetiolog
exacerb
note
sinc
current
commonli
agre
definit
aecopd
current
case
definit
includ
microbiolog
endpoint
impact
aecopd
healthrel
qualityoflif
healthcar
use
assess
order
provid
complet
pictur
diseas
burden
interact
airway
infect
system
manifest
copd
nutrit
statu
also
assess
biolog
specimen
collect
studi
may
also
use
diseaserel
test
includ
copd
explor
cellmedi
immun
respons
specif
bacteri
antigen
develop
noninvas
bacteri
diagnost
method
knowledg
studi
employ
realtim
electron
track
symptom
identifi
aecopd
potenti
aetiolog
trigger
import
sinc
avail
data
suggest
exacerb
may
report
healthcar
provid
consequ
exacerb
rate
lower
studi
employ
eventbas
criteria
defin
aecopd
due
close
daili
monitor
symptom
identifi
aecopd
anticip
exacerb
rate
studi
higher
previous
report
close
monitor
earli
therapeut
intervent
exacerb
may
also
impact
estim
overal
burden
diseas
number
epidemiolog
studi
initi
recent
year
character
understand
natur
histori
aecopd
howev
studi
includ
molecular
microbiolog
assess
recent
larg
observ
studi
focus
biomark
discoveri
involv
close
phenotyp
copd
patient
studi
aetiolog
exacerb
depth
anoth
studi
potenti
pathogen
bacteri
strain
identifi
use
molecular
type
techniqu
although
virus
potenti
airway
pathogen
investig
recent
preval
load
airway
bacteria
stabl
exacerb
aecopd
assess
pair
sampl
patient
particip
london
copd
cohort
studi
use
modern
molecular
techniqu
airway
bacteri
preval
load
found
increas
significantli
aecopd
quantit
molecular
techniqu
prove
discriminatori
cultur
howev
assess
limit
aeri
sampl
acquir
aecopd
stabl
diseas
analys
wide
rang
potenti
pathogen
bacteria
virus
use
advanc
pcrbase
techniqu
well
tradit
culturebas
method
major
strength
aeri
studi
design
comprehens
assess
clinic
statu
microbiolog
function
statu
nutrit
statu
healthrel
qualityoflif
healthcar
resourc
utilis
individu
patient
singl
larg
cohort
stabl
copd
aecopd
analys
propos
studi
gener
epidemiolog
data
complement
deriv
exist
copd
cohort
explor
determin
copd
contribut
bacteri
viral
pathogen
aecopd
well
provid
understand
limit
exist
data
exacerb
visit
trigger
patient
diari
data
accur
time
diari
complet
essenti
subject
particip
studi
receiv
diari
train
enrol
support
avail
studi
team
time
promot
accur
complet
diari
keep
cohort
retent
key
factor
success
deliveri
studi
indepth
sampl
protocol
particip
engag
comfort
feedback
key
factor
optimis
cohort
retent
comprehens
data
collect
identif
novel
approach
prevent
aecopd
import
research
goal
longact
betaagonist
laba
longact
antimuscarin
bronchodil
remain
cornerston
treatment
patient
copd
combin
laba
inhal
corticosteroid
also
use
patient
sever
diseas
andor
frequent
exacerb
longterm
treatment
numer
approach
investig
prevent
aecopd
includ
antiinflammatori
drug
immunomodulatori
agent
immunotherapi
antioxid
nonpharmacolog
strategi
vaccin
anoth
potenti
approach
merit
investig
reduc
aecopd
risk
howev
optim
strategi
target
key
respiratori
pathogen
yet
avail
clinician
conclus
consider
advanc
understand
epidemiolog
pathophysiolog
clinic
manag
copd
recent
year
howev
remain
genuin
need
explor
aetiolog
pathogenesi
aecopd
anticip
result
epidemiolog
studi
increas
understand
contribut
bacteri
viral
pathogen
aecopd
potenti
lead
research
target
therapeut
prevent
intervent
contributor
bourn
principl
investig
close
involv
step
studi
specif
wrote
substanti
part
protocol
c
cohet
epidemiologist
respons
observ
studi
close
involv
design
studi
v
kim
barton
coinvestig
close
involv
conduct
studi
tuck
site
project
manag
microbiolog
test
remain
genuin
need
explor
aetiolog
pathogenesi
aecopd
anticip
result
studi
increas
understand
contribut
bacteri
viral
pathogen
aecopd
potenti
lead
research
target
therapeut
prevent
intervent
conduct
specialis
hospit
extens
experi
respiratori
research
comprehens
assess
clinic
statu
microbiolog
function
statu
nutrit
statu
healthrel
qualityoflif
healthcar
resourc
utilis
individu
patient
singl
larg
cohort
stabl
copd
aecopd
aecopd
proactiv
identifi
patientcomplet
electron
diari
cohort
retent
key
factor
success
deliveri
studi
indepth
sampl
protocol
particip
engag
comfort
feedback
key
factor
optimis
cohort
retent
comprehens
data
collect
consider
progress
made
concern
epidemiolog
pathophysiolog
clinic
manag
copd
recent
year
howev
signific
challeng
remain
improv
understand
acut
exacerb
copd
aecopd
key
research
prioriti
aecopd
highli
relev
clinic
major
caus
copdrel
morbid
mortal
well
account
substanti
proport
signific
social
healthcar
econom
burden
copd
estim
aecopd
account
approxim
total
healthcar
cost
associ
copd
patient
global
initi
chronic
obstruct
lung
diseas
gold
stage
ii
diseas
experi
exacerb
annual
exacerb
vari
patient
patient
sever
diseas
variou
trigger
aecopd
identifi
howev
exacerb
associ
detect
molecular
diagnost
type
techniqu
use
describ
dynam
airway
infect
potenti
associ
clinic
outcom
studi
also
assess
impact
aecopd
healthrel
qualityoflif
healthcar
resourc
utilis
well
possibl
interact
diseas
endotyp
exacerb
primari
object
aeri
studi
estim
incid
allcaus
aecopd
aecopd
sputum
contain
bacteri
pathogen
overal
speci
secondari
studi
object
summaris
tabl
tabl
overview
primari
secondari
object
aeri
studi
level
object
primari
estim
incid
rate
allcaus
aecopd
estim
incid
rate
aecopd
sputum
contain
bacteri
pathogen
overal
speci
describ
proport
overal
specif
bacteri
pathogen
detect
sputum
sever
aecopd
describ
proport
overal
specif
bacteri
pathogen
detect
sputum
stabl
copd
estim
incid
rate
aecopd
sputum
contain
viral
pathogen
overal
speci
describ
proport
overal
specif
viral
pathogen
detect
sputum
sever
aecopd
estim
time
elaps
consecut
aecopd
episod
assess
impact
allcaus
aecopd
stabl
copd
healthrel
qualityoflif
assess
impact
healthcar
use
allcaus
aecopd
ongo
singlecentr
prospect
observ
cohort
studi
base
univers
hospit
southampton
uk
male
addit
daili
monitor
undertaken
patientcomplet
electron
diari
card
wide
rang
studi
procedur
perform
studi
entri
schedul
monthli
visit
exacerb
visit
tabl
tabl
overview
studi
assess
perform
schedul
monthli
visit
exacerb
visit
posteroanterior
chest
xray
later
requir
perform
exacerb
visit
per
standard
clinic
practic
order
exclud
pneumonia
variou
outcom
assess
quarterli
exacerb
use
seri
questionnair
patientreport
outcom
instrument
copd
assess
test
cat
nottingham
extend
daili
activ
scale
neadl
council
nutrit
appetit
questionnair
cnaq
five
item
includ
index
mobil
selfcar
usual
activ
paindiscomfort
anxietydepress
bode
index
bodymass
capac
also
calcul
healthcar
use
record
visit
includ
medic
vaccin
oxygen
therapi
use
mechan
ventil
pulmonari
rehabilit
treatment
surgic
intervent
outpati
visit
includ
gp
visit
telephon
contact
copd
team
emerg
room
visit
hospitalis
product
loss
time
miss
work
usual
activ
due
worsen
copd
symptom
potenti
chang
diseas
manag
follow
exacerb
eg
chang
medic
use
also
record
wide
rang
biolog
specimen
collect
studi
particip
tabl
blood
sampl
collect
patient
studi
entri
quarterli
exacerb
sputum
sampl
obtain
spontan
expector
induc
cultur
isol
also
store
addit
laboratori
test
perform
gsk
design
laboratori
sampl
size
calcul
base
primari
studi
endpoint
incid
allcaus
aecopd
assum
averag
subject
observ
period
sampl
size
subject
ensur
suffici
precis
estim
incid
rate
allcaus
aecopd
addit
order
follow
effect
subject
given
fact
subject
may
elig
withdraw
quit
earli
studi
possibl
due
deterior
subject
health
decis
taken
replac
subject
withdrew
first
year
followup
recruit
addit
subject
construct
consort
diagram
captur
possibl
reason
screen
failur
dropout
loss
followup
coprimari
studi
endpoint
occurr
allcaus
aecopd
occurr
aecopd
sputum
contain
bacteri
pathogen
detect
cultur
overal
speci
proport
subject
visit
sputum
sampl
obtain
comput
overal
method
sampl
obtain
spontan
induc
proport
sputum
sampl
obtain
visit
posit
specif
bacteri
pathogen
overal
bacteri
speci
also
calcul
incid
rate
allcaus
aecopd
aecopd
sputum
contain
bacteri
pathogen
overal
bacteri
speci
calcul
ci
ci
incid
rate
comput
use
model
account
repeat
event
name
generalis
linear
model
assum
neg
binomi
distribut
respons
variabl
logarithm
link
function
logarithm
time
followup
offset
variabl
preliminari
approach
flexibl
approach
statist
analysi
may
also
use
addit
model
covari
eg
smoke
statu
enrol
number
moderatesever
exacerb
report
month
prior
enrol
presenc
respiratori
pathogen
bacteria
detect
exacerb
visit
previou
visit
appli
incid
rate
also
calcul
moder
aecopd
sever
aecopd
aeri
studi
conduct
accord
declar
helsinki
good
clinic
practic
guidelin
approv
relev
institut
ethic
review
board
subject
must
provid
written
inform
consent
particip
result
obtain
dissemin
present
intern
medic
confer
peerreview
public
report
accord
strobe
guidanc
aeri
studi
initi
comprehens
assess
role
infecti
pathogen
aecopd
wellcharacteris
cohort
patient
studi
aim
explor
dynam
airway
infect
possibl
contribut
aecopd
well
potenti
role
chronic
colon
stabl
diseas
overal
object
studi
aim
refin
case
definit
aecopd
reflect
possibl
microbiolog
aetiolog
exacerb
note
sinc
current
commonli
agre
definit
aecopd
current
case
definit
includ
microbiolog
endpoint
impact
aecopd
healthrel
qualityoflif
healthcar
use
assess
order
provid
complet
pictur
diseas
burden
interact
airway
infect
system
manifest
copd
nutrit
statu
also
assess
detail
first
time
biolog
specimen
collect
studi
may
also
use
diseaserel
test
includ
molecular
type
describ
compar
knowledg
studi
employ
realtim
electron
track
symptom
identifi
aecopd
potenti
aetiolog
trigger
import
sinc
avail
data
suggest
exacerb
may
report
healthcar
provid
consequ
exacerb
rate
lower
studi
employ
eventbas
criteria
defin
aecopd
due
close
daili
monitor
symptom
identifi
aecopd
anticip
exacerb
rate
studi
higher
previous
report
close
monitor
earli
therapeut
intervent
exacerb
may
also
impact
estim
overal
burden
diseas
number
epidemiolog
studi
initi
recent
year
character
understand
natur
histori
aecopd
howev
import
recognis
studi
includ
molecular
microbiolog
assess
recent
larg
observ
studi
focus
biomark
discoveri
involv
close
phenotyp
copd
patient
studi
aetiolog
exacerb
depth
anoth
studi
potenti
pathogen
bacteri
strain
identifi
use
molecular
type
techniqu
although
virus
potenti
airway
pathogen
investig
recent
preval
load
airway
bacteria
stabl
exacerb
aecopd
assess
pair
sampl
patient
particip
london
copd
cohort
studi
use
modern
molecular
techniqu
airway
bacteri
preval
load
found
increas
significantli
aecopd
quantit
molecular
techniqu
prove
discriminatori
cultur
howev
assess
aeri
sampl
acquir
aecopd
stabl
diseas
analys
wide
rang
potenti
pathogen
bacteria
virus
use
advanc
pcrbase
techniqu
well
tradit
culturebas
method
numer
approach
investig
prevent
aecopd
includ
antiinflammatori
drug
immunomodulatori
agent
immunotherapi
antioxid
nonpharmacolog
strategi
vaccin
anoth
potenti
approach
merit
investig
reduc
aecopd
risk
howev
optim
strategi
target
key
respiratori
pathogen
yet
avail
clinician
conclus
consider
advanc
understand
epidemiolog
pathophysiolog
clinic
manag
copd
recent
year
howev
remain
genuin
need
explor
aetiolog
pathogenesi
aecopd
anticip
result
epidemiolog
studi
increas
understand
contribut
bacteri
viral
pathogen
aecopd
natur
histori
event
associ
time
symptom
physiolog
chang
offer
new
direct
research
target
therapeut
prevent
intervent
remain
genuin
need
explor
aetiolog
pathogenesi
aecopd
anticip
result
studi
increas
understand
contribut
bacteri
viral
pathogen
aecopd
potenti
lead
research
target
therapeut
prevent
intervent
conduct
specialis
hospit
extens
experi
respiratori
research
comprehens
assess
clinic
statu
microbiolog
function
statu
nutrit
statu
healthrel
qualityoflif
healthcar
resourc
utilis
individu
patient
singl
larg
cohort
stabl
copd
aecopd
aecopd
proactiv
identifi
patientcomplet
electron
diari
cohort
retent
key
factor
success
deliveri
studi
indepth
sampl
protocol
particip
engag
comfort
feedback
key
factor
optimis
cohort
retent
comprehens
data
collect
consider
progress
made
concern
epidemiolog
pathophysiolog
clinic
manag
copd
recent
year
howev
signific
challeng
remain
improv
understand
acut
exacerb
copd
aecopd
key
research
prioriti
aecopd
highli
relev
clinic
major
caus
copdrel
morbid
mortal
well
account
substanti
proport
signific
social
healthcar
econom
burden
copd
estim
aecopd
account
approxim
total
healthcar
cost
associ
copd
patient
global
initi
chronic
obstruct
lung
diseas
gold
stage
ii
diseas
experi
exacerb
annual
exacerb
vari
patient
patient
sever
diseas
variou
trigger
aecopd
identifi
howev
exacerb
associ
detect
bacteri
andor
viral
respiratori
pathogen
exacerb
associ
detect
respiratori
pathogen
shown
mark
impact
primari
object
aeri
studi
estim
incid
allcaus
aecopd
aecopd
sputum
contain
bacteri
pathogen
overal
speci
secondari
studi
object
summaris
tabl
overview
primari
secondari
object
aeri
studi
level
object
primari
estim
incid
rate
allcaus
aecopd
estim
incid
rate
aecopd
sputum
contain
bacteri
pathogen
overal
speci
describ
proport
overal
specif
bacteri
pathogen
detect
sputum
sever
aecopd
describ
proport
overal
specif
bacteri
pathogen
detect
sputum
stabl
copd
estim
incid
rate
aecopd
sputum
contain
viral
pathogen
overal
speci
describ
proport
overal
specif
viral
pathogen
detect
sputum
sever
aecopd
ongo
singlecentr
prospect
observ
cohort
studi
base
univers
hospit
southampton
uk
male
addit
daili
monitor
undertaken
patientcomplet
electron
diari
card
wide
rang
studi
procedur
perform
studi
entri
schedul
monthli
visit
exacerb
visit
tabl
posteroanterior
chest
xray
later
requir
perform
exacerb
visit
per
standard
clinic
practic
order
exclud
pneumonia
variou
outcom
assess
quarterli
exacerb
use
seri
questionnair
patientreport
outcom
instrument
copd
assess
test
cat
nottingham
extend
daili
activ
scale
neadl
council
nutrit
appetit
questionnair
cnaq
five
item
includ
index
mobil
selfcar
usual
activ
paindiscomfort
anxietydepress
bode
index
bodymass
index
degre
airflow
obstruct
level
function
dyspnea
exercis
capac
also
calcul
healthcar
use
record
visit
includ
medic
vaccin
oxygen
therapi
use
mechan
ventil
pulmonari
rehabilit
treatment
surgic
intervent
outpati
visit
includ
gp
visit
telephon
contact
copd
team
emerg
room
visit
hospitalis
product
loss
time
miss
work
usual
activ
due
worsen
copd
symptom
potenti
chang
diseas
manag
follow
exacerb
eg
chang
medic
use
also
record
wide
rang
biolog
specimen
collect
studi
particip
tabl
blood
sampl
collect
patient
studi
entri
quarterli
exacerb
sputum
sampl
obtain
spontan
expector
induc
cultur
isol
also
store
addit
laboratori
test
perform
gsk
design
laboratori
sampl
size
calcul
base
primari
studi
endpoint
incid
sampl
size
subject
ensur
suffici
precis
estim
incid
rate
allcaus
aecopd
addit
order
follow
effect
subject
given
fact
subject
may
elig
withdraw
quit
earli
studi
possibl
due
deterior
subject
health
decis
taken
replac
subject
withdrew
first
year
followup
recruit
addit
subject
construct
consort
diagram
captur
possibl
reason
screen
failur
dropout
loss
followup
coprimari
studi
endpoint
occurr
allcaus
aecopd
occurr
aecopd
sputum
contain
bacteri
pathogen
detect
cultur
overal
speci
proport
subject
visit
sputum
sampl
obtain
comput
overal
method
sampl
obtain
spontan
induc
proport
sputum
sampl
obtain
visit
posit
specif
bacteri
pathogen
overal
bacteri
speci
also
calcul
incid
rate
allcaus
aecopd
aecopd
sputum
contain
bacteri
pathogen
overal
bacteri
speci
calcul
ci
ci
incid
rate
comput
use
model
account
repeat
event
name
generalis
linear
model
assum
neg
binomi
distribut
respons
variabl
logarithm
link
function
logarithm
time
followup
offset
variabl
preliminari
approach
flexibl
approach
statist
analysi
may
also
use
addit
model
covari
eg
smoke
statu
enrol
number
moderatesever
exacerb
report
month
prior
enrol
presenc
respiratori
pathogen
bacteria
detect
exacerb
visit
previou
visit
appli
incid
rate
also
calcul
moder
aecopd
sever
aecopd
aeri
studi
conduct
accord
declar
helsinki
good
clinic
practic
guidelin
approv
relev
institut
ethic
review
board
subject
must
provid
written
inform
consent
particip
result
obtain
dissemin
present
intern
medic
confer
peerreview
public
report
accord
strobe
guidanc
aeri
studi
initi
comprehens
assess
role
infecti
pathogen
aecopd
wellcharacteris
cohort
patient
studi
aim
atot
explor
dynam
airway
infect
possibl
contribut
aecopd
well
potenti
role
chronic
colon
stabl
diseas
overal
object
studi
aim
refin
case
definit
aecopd
reflect
possibl
microbiolog
aetiolog
exacerb
note
sinc
current
commonli
agre
definit
aecopd
current
case
definit
includ
microbiolog
endpoint
impact
aecopd
healthrel
qualityoflif
healthcar
use
assess
order
provid
complet
pictur
diseas
burden
interact
airway
infect
system
manifest
copd
nutrit
statu
also
assess
detail
first
time
biolog
specimen
collect
studi
may
also
use
diseaserel
test
includ
molecular
type
describ
compar
knowledg
studi
employ
realtim
electron
track
symptom
identifi
aecopd
potenti
aetiolog
trigger
import
sinc
avail
data
suggest
exacerb
may
report
healthcar
provid
consequ
exacerb
rate
lower
studi
employ
eventbas
criteria
defin
aecopd
due
close
daili
monitor
symptom
identifi
aecopd
anticip
exacerb
rate
studi
higher
previous
report
close
monitor
earli
therapeut
intervent
exacerb
may
also
impact
estim
overal
burden
diseas
number
epidemiolog
studi
initi
recent
year
character
understand
natur
histori
aecopd
howev
import
recognis
studi
includ
molecular
microbiolog
assess
recent
larg
observ
studi
focus
biomark
discoveri
involv
close
phenotyp
copd
patient
studi
aetiolog
exacerb
depth
anoth
studi
potenti
pathogen
bacteri
strain
identifi
use
molecular
type
techniqu
although
virus
potenti
airway
pathogen
investig
recent
preval
load
airway
bacteria
stabl
exacerb
aecopd
assess
pair
sampl
patient
particip
london
copd
cohort
studi
use
modern
molecular
techniqu
airway
bacteri
preval
load
found
increas
significantli
aecopd
quantit
molecular
techniqu
prove
discriminatori
cultur
howev
assess
pneumonia
catarrhali
howev
potenti
pathogen
overal
respiratori
microbiom
may
also
contribut
yet
studi
detail
aeri
sampl
acquir
aecopd
stabl
diseas
analys
wide
rang
potenti
pathogen
bacteria
virus
use
advanc
pcrbase
techniqu
well
tradit
culturebas
method
major
strength
aeri
studi
design
comprehens
assess
clinic
statu
microbiolog
function
statu
nutrit
statu
healthrel
qualityoflif
healthcar
resourc
utilis
individu
patient
singl
larg
cohort
stabl
copd
aecopd
select
subject
histori
least
singl
exacerb
enrich
cohort
degre
ensur
adequ
number
exacerb
sampl
accept
aspect
analysi
may
generaliz
subgroup
patient
never
exacerb
analys
propos
studi
gener
epidemiolog
data
complement
deriv
exist
copd
cohort
explor
determin
copd
contribut
bacteri
viral
pathogen
aecopd
well
provid
understand
limit
exist
data
exacerb
visit
trigger
patient
diari
data
accur
time
diari
complet
essenti
subject
particip
studi
receiv
diari
train
enrol
support
avail
studi
team
time
promot
accur
complet
diari
keep
cohort
retent
key
factor
success
deliveri
studi
indepth
sampl
protocol
particip
engag
comfort
feedback
key
factor
optimis
cohort
retent
comprehens
data
collect
combin
laba
inhal
corticosteroid
also
use
patient
sever
diseas
andor
frequent
exacerb
longterm
treatment
macrolid
antibiot
puls
quinolon
therapi
may
consid
exacerb
prevent
howev
concern
exist
potenti
develop
antimicrobi
resist
longterm
antibiot
therapi
numer
approach
investig
prevent
aecopd
includ
antiinflammatori
drug
immunomodulatori
agent
immunotherapi
antioxid
nonpharmacolog
strategi
vaccin
anoth
potenti
approach
merit
investig
reduc
aecopd
risk
howev
optim
strategi
target
key
respiratori
pathogen
yet
avail
clinician
conclus
consider
advanc
understand
epidemiolog
pathophysiolog
clinic
manag
copd
recent
year
howev
remain
genuin
need
explor
aetiolog
pathogenesi
aecopd
anticip
result
epidemiolog
studi
increas
understand
contribut
bacteri
viral
pathogen
aecopd
natur
histori
event
associ
time
symptom
physiolog
chang
offer
new
direct
potenti
lead
research
target
therapeut
prevent
intervent
contributor
bourn
principl
investig
close
involv
step
studi
specif
wrote
substanti
part
protocol
c
cohet
eepidemiologist
respons
observ
studi
close
involv
design
studi
v
kim
barton
coinvestig
close
involv
wilkinson
receiv
institut
grant
glaxosmithklin
gsk
group
compani
conduct
studi
bourn
report
receiv
grant
advisori
board
fee
assist
attend
confer
gsk
also
receiv
fee
lectur
advisori
board
teach
novarti
astra
zeneca
boehring
ingelheim
clark
also
receiv
project
grant
support
confer
fund
attend
advisori
board
payment
pfizer
gsk
novarti
payment
made
employ
institut
wilkinson
also
receiv
travel
expens
fee
advisori
board
gsk
relat
studi
fee
advisori
board
pfizer
astrazeneca
reimburs
travel
confer
attend
